Table 1.

Patient characteristics according to treatment³

	France				Spain				UK
	All patients (n=1,374)	Biologic treatment (n=125)	Nonbiologic treatment (n=1,249)	P-valueb	All patients (n=561)	Biologic treatment (n=109)	Nonbiologic treatment (n=452)	P-valueb	All patients (n=574)	Biologic treatment (n=48)	Nonbiologic treatment (n=526)	P-valueb
Mean age, years	46.6	50.4	46.3	0.0005	42.4	42.8	42.3	0.77	43.9	44.3	43.8	0.82
Male	769 (56.0%)	78 (62.4%)	691 (55.3%)	0.13	329 (58.7%)	71 (65.1%)	258 (57.1%)	0.12	301 (52.4%)	25 (52.1%)	276 (52.5%)	0.96
Mean length of diagnosis, years	9.2	15.0	8.6	<0.0001	9.5	11.8	8.8	0.0186	12.4	14.8	12.2	0.16
BMI ≥30c	135 (9.8%)	26 (21.0%)	109 (8.7%)	<0.0001	52 (9.3%)	18 (16.5%)	34 (7.6%)	0.003	86 (15.0%)	14 (29.2%)	72 (13.7%)	0.2
Mean PASI scored	9.9	14.7	9.4	<0.0001	9.6	12.9	8.6	0.0005	10.4	13.0	10.2	0.10
Nail involvement	355 (25.8%)	60 (48.0%)	295 (23.6%)	<0.000l	165 (29.4%)	53 (48.6%)	112(24.8%)	<0.0001	244 (42.5%)	24 (50.0%)	220 (41.8%)	0.27
Psoriatic arthritise	127(9.2%)	44 (35.2%)	83 (6.6%)	<0.000l	35 (6.2%)	17 (15.6%)	18 (3.9%)	<0.0001	75 (13.0%)	22 (45.8%)	53 (10.0%)	<0.000l

Notes:

^aA total of 79 patients were excluded from 2,588 patients; all values are percentages unless otherwise indicated;

^bP-values are for the comparison between biologic users and nonusers in each country;

^cBMI data were available for only 1,369 patients from France, 557 patients from Spain, and 360 patients from the UK;

^dmean PASI scores were calculated from measured or imputed data for 1,270, 481, and 538 patients from France, Spain, and the UK, respectively;

^epsoriatic arthritis was reported for only 1,374 patients from France, 546 patients from Spain, and 570 patients from the UK.

Abbreviations: BMI, body mass index; CI, confidence interval; PASI, Psoriasis Area and Severity Index.